Biogen Hedged Its Bet and Won Big [The Motley Fool]
Biogen Inc. (BIIB)
Last biogen inc. earnings: 4/22 07:12 am
Check Earnings Report
US:NASDAQ Investor Relations:
biogen.com/en_us/investors.html
Company Research
Source: The Motley Fool
Biogen Hedged Its Bet and Won Big -- The Motley Fool Get The Motley Fool's Free to Build Wealth Report Motley Fool Co-Founders just released an exclusive report naming of their favorite stocks to buy right now… Send me stocks Biogen Hedged Its Bet and Won Big The biotech had $. billion in sales at risk. ( TMFBiologyFool Sometimes a drugmaker's best move isn't developing a new drug but protecting sales of an established one. Sales of Biogen's NASDAQ:BIIB NASDAQ:ALKS Vumerity and Tecfidera are almost the same drug. The chemical name for Vumerity is diroximel fumarate, while Tecfidera is dimethyl fumarate. The base "fumarate" is the part that does the work, with both drugs breaking down into monomethyl fumarate. Tecfidera is a great drug, reducing the rate of multiple sclerosis attacks, and it can be taken orally, while many of the older multiple sclerosis drugs have to be injected or infused -- hence the multibillion-dollar sales. But Tecfidera causes gastrointestinal issues -- diarr
Show less
Read more
Impact Snapshot
Event Time:
BIIB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BIIB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIIB alerts
High impacting Biogen Inc. news events
Weekly update
A roundup of the hottest topics
BIIB
News
- Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at HC Wainwright from $325.00 to $300.00. They now have a "buy" rating on the stock.MarketBeat
- Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake [Yahoo! Finance]Yahoo! Finance
- Biogen (BIIB) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates [Yahoo! Finance]Yahoo! Finance
- Biogen Inc. (NASDAQ: BIIB) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $294.00 price target on the stock.MarketBeat
- Should You Be Confident in Biogen (BIIB)? [Yahoo! Finance]Yahoo! Finance
BIIB
Earnings
- 4/24/24 - Beat
BIIB
Sec Filings
- 4/24/24 - Form 10-Q
- 4/24/24 - Form 8-K
- 4/12/24 - Form PRE
- BIIB's page on the SEC website